Safety and efficacy of AIN457 in patients with active non-infectious uveitis

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221051

Enrollment

208

Registered

2010-03-31

Start date

2010-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-infectiouse uveitis

Interventions

investigational material(s) Generic name etc : AIN457 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Male and female subjects 18 years of age or older - Patients with diagnosis of chronic non-infectious intermediate uveitis, posterior uveitis or panuveitis in at least one eye - Evidence of active intermediate, posterior or panuveitis at screening and baseline in at least one eye - Requirement for any of the immunosuppressive therapies for the treatment or prevention of uveitis

Exclusion criteria

Exclusion criteria: - Patients with a primary diagnosis of Behcet's disease or anterior uveitis - Any intermediate uveitis, posterior uveitis or panuveitis in which the manifestation(s) of the active intraocular inflammatory disease may spontaneously resolve or that are not characterized by the presence of either anterior chamber cells or vitritis such as the white dot retino-choroidopathies - Patients with infectious uveitis

Design outcomes

Primary

Measure	Time frame
mean change in vitreous haze grade in the study eye from baseline to 28 weeks	—

Secondary

Measure	Time frame
change in immunosuppressive medication score from baseline to Week 28	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026